Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Cannabis-Derived Epilepsy Drug Sales Double, GW Stock Surges

Stockhouse Editorial
0 Comments| August 7, 2019

GW Pharmaceuticals (NASDAQ: GWPH) saw its share price spike on Wednesday after reporting its marijuana-derived epilepsy drug more than doubled in sales. This comes via its Q2 2019 earnings report released this week, which led to two stock analysts to boost their price targets for the company.

GWPH stock leaped more than 12% ($18.59 USD) to $171.01 in premarket trading. The shares were up 6.65%, or $10.13, at $162.46 in early trading, peaking as high as $167.

Clocking in at $68.4 million, far above analyst estimates of $40.9 million, sales of its cannabis-derived epilepsy drug Epidiolex more than doubled from the previous quarter. Revenue for the quarter ended June 30th, 2019 was $72.0 million compared to $3.3 million for the quarter ended June 30th, 2018. Analysts at Stifel Nicolaus and Oppenheimer and others have raised their stock price targets on GW Pharma.

More than 12,000 patients have received Epidiolex prescriptions since launch and more than 2,500 physicians have generated dispensed prescriptions in that time.

One of Epifiolex’s key ingredients is cannabidiol, a compound in cannabis plants that is being used to treat specific types of epilepsy.

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Metals & Mining

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.